These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 29599452)

  • 1. Direct antiviral properties of TLR ligands against HBV replication in immune-competent hepatocytes.
    Lucifora J; Bonnin M; Aillot L; Fusil F; Maadadi S; Dimier L; Michelet M; Floriot O; Ollivier A; Rivoire M; Ait-Goughoulte M; Daffis S; Fletcher SP; Salvetti A; Cosset FL; Zoulim F; Durantel D
    Sci Rep; 2018 Mar; 8(1):5390. PubMed ID: 29599452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights on the antiviral mechanisms of action of the TLR1/2 agonist Pam3CSK4 in hepatitis B virus (HBV)-infected hepatocytes.
    Desmares M; Delphin M; Chardès B; Pons C; Riedinger J; Michelet M; Rivoire M; Verrier B; Salvetti A; Lucifora J; Durantel D
    Antiviral Res; 2022 Oct; 206():105386. PubMed ID: 35963549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.
    Niu C; Li L; Daffis S; Lucifora J; Bonnin M; Maadadi S; Salas E; Chu R; Ramos H; Livingston CM; Beran RK; Garg AV; Balsitis S; Durantel D; Zoulim F; Delaney WE; Fletcher SP
    J Hepatol; 2018 May; 68(5):922-931. PubMed ID: 29247725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toll-like receptor dual-acting agonists are potent inducers of PBMC-produced cytokines that inhibit hepatitis B virus production in primary human hepatocytes.
    Janovec V; Hodek J; Clarova K; Hofman T; Dostalik P; Fronek J; Chlupac J; Chaperot L; Durand S; Baumert TF; Pichova I; Lubyova B; Hirsch I; Weber J
    Sci Rep; 2020 Jul; 10(1):12767. PubMed ID: 32728070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Toll-like receptor 2 in the immune response against hepadnaviral infection.
    Zhang X; Ma Z; Liu H; Liu J; Meng Z; Broering R; Yang D; Schlaak JF; Roggendorf M; Lu M
    J Hepatol; 2012 Sep; 57(3):522-8. PubMed ID: 22617154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells.
    Wu J; Meng Z; Jiang M; Pei R; Trippler M; Broering R; Bucchi A; Sowa JP; Dittmer U; Yang D; Roggendorf M; Gerken G; Lu M; Schlaak JF
    Hepatology; 2009 Apr; 49(4):1132-40. PubMed ID: 19140219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of Pattern Recognition Receptor Ligands on Induction of Innate Immunity and Control of Hepatitis B Virus Infection.
    Asadi-Asadabad S; Sarvnaz H; Amiri MM; Mobini M; Khoshnoodi J; Hojjat-Farsangi M; Jeddi-Tehrani M; Golsaz-Shirazi F; Shokri F
    Viral Immunol; 2021 Oct; 34(8):531-541. PubMed ID: 34030480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Toll-like receptor dependent innate immune responses by primary mouse hepatocytes and its control of HBV replication].
    Wu J; Chen MF; Xia YC; Guo Y; Lin Y; Sun C; Zhang CY; Chen Y; Liu SP; Hao YH; Lu MJ; Schlaak JF; Yang DL
    Zhonghua Gan Zang Bing Za Zhi; 2011 Nov; 19(11):838-42. PubMed ID: 22433306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses.
    Ma Z; Zhang E; Yang D; Lu M
    Cell Mol Immunol; 2015 May; 12(3):273-82. PubMed ID: 25418467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral activity of various interferons and pro-inflammatory cytokines in non-transformed cultured hepatocytes infected with hepatitis B virus.
    Isorce N; Testoni B; Locatelli M; Fresquet J; Rivoire M; Luangsay S; Zoulim F; Durantel D
    Antiviral Res; 2016 Jun; 130():36-45. PubMed ID: 26971407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice.
    Wu J; Lu M; Meng Z; Trippler M; Broering R; Szczeponek A; Krux F; Dittmer U; Roggendorf M; Gerken G; Schlaak JF
    Hepatology; 2007 Dec; 46(6):1769-78. PubMed ID: 17929296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells.
    Guo H; Jiang D; Ma D; Chang J; Dougherty AM; Cuconati A; Block TM; Guo JT
    J Virol; 2009 Jan; 83(2):847-58. PubMed ID: 18971270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon.
    Mutz P; Metz P; Lempp FA; Bender S; Qu B; Schöneweis K; Seitz S; Tu T; Restuccia A; Frankish J; Dächert C; Schusser B; Koschny R; Polychronidis G; Schemmer P; Hoffmann K; Baumert TF; Binder M; Urban S; Bartenschlager R
    Gastroenterology; 2018 May; 154(6):1791-1804.e22. PubMed ID: 29410097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B virus sensitivity to interferon-α in hepatocytes is more associated with cellular interferon response than with viral genotype.
    Shen F; Li Y; Wang Y; Sozzi V; Revill PA; Liu J; Gao L; Yang G; Lu M; Sutter K; Dittmer U; Chen J; Yuan Z
    Hepatology; 2018 Apr; 67(4):1237-1252. PubMed ID: 29059468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly(I:C) treatment leads to interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model.
    Wu J; Huang S; Zhao X; Chen M; Lin Y; Xia Y; Sun C; Yang X; Wang J; Guo Y; Song J; Zhang E; Wang B; Zheng X; Schlaak JF; Lu M; Yang D
    J Virol; 2014 Sep; 88(18):10421-31. PubMed ID: 24920792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Retinoic Acid Receptor Agonists as Potent Hepatitis B Virus Inhibitors via a Drug Repurposing Screen.
    Li B; Wang Y; Shen F; Wu M; Li Y; Fang Z; Ye J; Wang L; Gao L; Yuan Z; Chen J
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30224536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and functionality of Toll- and RIG-like receptors in HepaRG cells.
    Luangsay S; Ait-Goughoulte M; Michelet M; Floriot O; Bonnin M; Gruffaz M; Rivoire M; Fletcher S; Javanbakht H; Lucifora J; Zoulim F; Durantel D
    J Hepatol; 2015 Nov; 63(5):1077-85. PubMed ID: 26144659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection.
    Zhang E; Lu M
    Med Microbiol Immunol; 2015 Feb; 204(1):11-20. PubMed ID: 25550115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-hepatitis B virus (HBV) response of imiquimod based toll like receptor 7 ligand in hbv-positive human hepatocelluar carcinoma cell line.
    Das D; Sengupta I; Sarkar N; Pal A; Saha D; Bandopadhyay M; Das C; Narayan J; Singh SP; Chakrabarti S; Chakravarty R
    BMC Infect Dis; 2017 Jan; 17(1):76. PubMed ID: 28088184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus.
    Volz T; Allweiss L; Ben MBarek M; Warlich M; Lohse AW; Pollok JM; Alexandrov A; Urban S; Petersen J; Lütgehetmann M; Dandri M
    J Hepatol; 2013 May; 58(5):861-7. PubMed ID: 23246506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.